GSK
British multinational pharmaceutical and biotechnology company
GSK London SE · home listing
GSK NYSE
ISIN GB0009252882 SEC CIK 1131399 LEI 5493000HZTVUYLO1D793
Follow GSK
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | £32.7B | £5.7B |
| FY24 | £31.4B | £2.6B |
| FY23 | £30.3B | £4.9B |
| FY22 | £29.3B | £15B |
| FY21 | £34.1B | £4.4B |
| FY20 | £34.1B | £5.7B |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 72.4% | 24.3% | 17.5% |
| FY24 | 71.2% | 12.8% | 8.2% |
| FY23 | 71.8% | 22.2% | 16.2% |
| FY22 | 67.4% | 21.9% | 51% |
| FY21 | 66% | 18.2% | 12.9% |
| FY20 | 65.7% | 22.8% | 16.9% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | £6.4B |
| FY24 | £5.2B |
| FY23 | £5.5B |
| FY22 | £6.3B |
| FY21 | £6.8B |
| FY20 | £7.2B |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | £2.6B | £1.4B |
| FY24 | £2.4B | - |
| FY23 | £2.2B | - |
| FY22 | £3.5B | - |
| FY21 | £4B | - |
| FY20 | £4B | - |
- GSK
- Healthcare median
Show the numbers
| Year | GSK | Healthcare median |
|---|---|---|
| FY25 | 17.5% | −30.8% |
| FY24 | 8.2% | −47% |
| FY23 | 16.2% | −58% |
| FY22 | 51% | −80.4% |
| FY21 | 12.9% | −71.9% |
| FY20 | 16.9% | −62.2% |